向LCK的分子粘剂克服了T细胞急性淋巴细胞白血病中基于抑制剂的治疗的耐药性
bioRxiv : the preprint server for biology
|July 17, 2025
概括
针对LCK激酶的新分子剂提供了针对T细胞急性淋巴细胞白血病 (T-ALL) 的有希望的策略. 这些降解剂通过与传统抑制剂不同地激活LCK来克服耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 对激酶抑制剂的耐药性是癌症治疗中的一个重要障碍.
- 向蛋白降解 (TPD) 是一种替代治疗方式,但其在抗性癌症中的有效性尚未完全理解.
研究的目的:
- 通过使用大脑细胞招募分子降解剂 (MGDs) 对抗耐药T细胞急性淋巴细胞白血病 (T-ALL) 的TPD潜力进行调查.
- 发现和优化针对T-ALL中的致癌性激酶LCK的MGD.
主要方法:
- 使用高通量查和药物化学优化来开发新的MGD.
- 结构-活动关系分析和三元复合模型阐明了LCK和CRBN之间的相互作用接口.
- 在T-ALL细胞系上进行了体外细胞毒性测试.
主要成果:
- 新型MGDs被开发出来,诱导CRBN-依赖的LCK降解和T-ALL.强大的细胞毒性.
- 确定了涉及LCK G环的非正规降解,这对MGD-CRBN相互作用至关重要.
- 这些MGD针对与ATP结合部位不同区域的LCK,逃避像守门员突变这样的抵抗机制.
结论:
- 针对LCK的MGD显示出潜在的潜力,作为一种克服T-ALL.中酶抑制剂耐药性的策略.
- 这种方法突出了治疗耐药癌症的潜在可通用TPD策略.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664


